OTC Markets OTCPK - Delayed Quote USD
Terumo Corporation (TRUMF)
At close: October 25 at 4:00 PM EDT
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
921,863,000.00
921,863,000.00
820,209,000.00
703,303,000.00
613,842,000.00
--
Cost of Revenue
442,688,000.00
442,688,000.00
402,839,000.00
333,962,000.00
287,219,000.00
--
Gross Profit
479,174,000.00
479,174,000.00
417,369,000.00
369,341,000.00
326,623,000.00
--
Operating Expense
339,079,000.00
339,079,000.00
300,036,000.00
253,381,000.00
228,237,000.00
--
Operating Income
140,095,000.00
140,095,000.00
117,333,000.00
115,960,000.00
98,386,000.00
--
Net Non Operating Interest Income Expense
754,000.00
754,000.00
-1,367,000.00
-1,899,000.00
-610,000.00
--
Pretax Income
140,829,000.00
140,829,000.00
116,137,000.00
114,501,000.00
97,060,000.00
--
Tax Provision
34,455,000.00
34,455,000.00
26,811,000.00
25,687,000.00
19,859,000.00
--
Net Income Common Stockholders
106,374,000.00
106,374,000.00
89,325,000.00
88,813,000.00
77,268,000.00
--
Diluted NI Available to Com Stockholders
106,374,000.00
106,374,000.00
89,325,000.00
88,813,000.00
77,268,000.00
--
Basic EPS
66.54
71.50
59.50
58.73
51.16
--
Diluted EPS
66.52
71.47
59.48
58.69
51.05
--
Basic Average Shares
1,488,934.54
1,487,748.25
1,501,229.02
1,512,418.10
1,510,195.70
--
Diluted Average Shares
1,489,512.59
1,488,372.74
1,501,871.05
1,513,321.85
1,513,526.36
--
Total Operating Income as Reported
140,096,000.00
140,096,000.00
117,332,000.00
115,960,000.00
98,386,000.00
--
Total Expenses
781,767,000.00
781,767,000.00
702,875,000.00
587,343,000.00
515,456,000.00
--
Net Income from Continuing & Discontinued Operation
106,374,000.00
106,374,000.00
89,325,000.00
88,813,000.00
77,268,000.00
--
Normalized Income
106,374,000.00
106,374,000.00
89,325,000.00
88,813,000.00
77,268,000.00
--
Interest Income
3,529,000.00
3,529,000.00
2,649,000.00
1,062,000.00
1,727,000.00
--
Interest Expense
2,775,000.00
2,775,000.00
4,016,000.00
2,961,000.00
2,337,000.00
--
Net Interest Income
754,000.00
754,000.00
-1,367,000.00
-1,899,000.00
-610,000.00
--
EBIT
143,604,000.00
143,604,000.00
120,153,000.00
117,462,000.00
99,397,000.00
--
EBITDA
220,349,000.00
220,349,000.00
190,391,000.00
176,344,000.00
153,329,000.00
--
Reconciled Cost of Revenue
442,688,000.00
442,688,000.00
402,839,000.00
333,962,000.00
287,219,000.00
--
Reconciled Depreciation
76,745,000.00
76,745,000.00
70,238,000.00
58,882,000.00
53,932,000.00
--
Net Income from Continuing Operation Net Minority Interest
106,374,000.00
106,374,000.00
89,325,000.00
88,813,000.00
77,268,000.00
--
Normalized EBITDA
220,349,000.00
220,349,000.00
190,391,000.00
176,344,000.00
153,329,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
3/31/2020 - 4/13/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
OCPNF Olympus Corporation
18.44
0.00%
CZMWF Carl Zeiss Meditec AG
66.53
0.00%
HOCPY HOYA Corporation
131.33
+0.61%
TFX Teleflex Incorporated
233.63
-0.84%
COO The Cooper Companies, Inc.
107.82
+0.48%
HOLX Hologic, Inc.
80.83
-0.10%
XRAY DENTSPLY SIRONA Inc.
23.31
-4.51%
LUCY Innovative Eyewear, Inc.
5.84
-4.73%
BAX Baxter International Inc.
35.97
-2.07%
WST West Pharmaceutical Services, Inc.
307.92
-6.87%